FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.
Feature|Articles|September 14, 2026
Why Fragmented Contract Processes Are Slowing Pharmaceutical Operations
Author(s)Tom Cowen
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
Advertisement
Advertisement
The pharmaceutical industry has made significant investments in digital transformation, ranging from AI-led drug discovery and clinical trial optimization to advanced analytics and real-world evidence generation. As a result, digital technologies are changing how the industry discovers, commercializes and delivers medicines.
Related to this article
Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Advertisement
Advertisement